Dossier assessment
Glofitamab (DLBCL, monotherapy, third line or later) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Glofitamab (DLBCL, monotherapy, third line or later) Benefit assessment according to §35a SGB V
-
Dossier assessment
Glofitamab (DLBCL, monotherapy, third line or later) Benefit assessment according to §35a SGB V
Dossier assessment
Adults with relapsed or refractory diffuse large B-cell lymphoma, after 2 or more lines of systemic therapy
- Patients who are eligible for CAR T-cell therapy or stem cell transplantation: added benefit not proven
- Patients who are ineligible for CAR T-cell therapy and stem cell transplantation: added benefit not proven
Project details
- Project no.
- A25-65
- Commission
- Commission awarded on 14.04.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-65_en
Connected Projects
-
Dossier assessment
Glofitamab (diffuse large B-cell lymphoma) – Assessment according to § 35a Social Code Book (SGB) V (1) Sentence 11
Status: Commission completed
-
Dossier assessment
Glofitamab (DLBCL, combination with gemcitabine and oxaliplatin) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed